Pio Therapeutics (Pio Tx) is a new company that will focus on expediting further development of its first-in-class agonist antibody, PIO-001. This is a selective agonistic anti-IL-21 monoclonal antibody that has been designed to amplify the bioactivity of endogenously produced IL-21, proportional to its localised expression. This approach will overcome clinical challenges associated with recombinant IL-21, take advantage of an antibody as a therapeutic modality, and allow combinatorial approaches with other therapeutics to be easily developed.

The research that led to the discovery and initial characterisation of PIO-001 was conducted at Monash University, in the laboratories of Professor Charles Mackay, Professor Di Yu, and Dr Remy Robert.

Click here for more information